| Autor: |
Florez, H., Reaven, P. D., Bahn, G., Moritz, T., Warren, S., Marks, J., Reda, D., Duckworth, W., Abraira, C., Hayward, R., Emanuele, N. |
| Předmět: |
|
| Zdroj: |
Diabetes, Obesity & Metabolism; Oct2015, Vol. 17 Issue 10, p949-955, 7p |
| Abstrakt: |
Aims To evaluate the relationship between patterns of rosiglitazone use and cardiovascular ( CV) outcomes in the Veterans Affairs Diabetes Trial ( VADT). Methods Time-dependent survival analyses, case-control and 1 : 1 propensity matching approaches were used to examine the relationship between patterns of rosiglitazone use and CV outcomes in the VADT, a randomized controlled study that assessed the effect of intensive glycaemic control on CV outcomes in 1791 patients with type 2 diabetes ( T2D) whose mean age was 60.4 ± 9 years. Participants were recruited between 1 December 2000 and 31 May 2003, and were followed for 5-7.5 years (median 5.6) with a final visit by 31 May 2008. Rosiglitazone (4 mg and 8 mg daily) was initiated per protocol in both the intensive-therapy and standard-therapy groups. Main outcomes included a composite CV outcome, CV death and myocardial infarction ( MI). Results Both daily doses of rosiglitazone were associated with lower risk for the primary composite CV outcome [4 mg: hazard ratio ( HR) 0.63, 95% confidence interval ( CI) 0.49-0.81 and 8 mg: HR 0.60, 95% CI 0.49-0.75] after adjusting for demographic and clinical covariates. A reduction in CV death was also observed ( HR 0.25, p < 0.001, for both 4 and 8 mg/day rosiglitazone); however, the effect on MI was less evident for 8 mg/day and not significant for 4 mg/day. Conclusions In older patients with T2D the use of rosiglitazone was associated with decreased risk of the primary CV composite outcome and CV death. Rosiglitazone use did not lead to a higher risk of MI. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text